Efficacy of IL‐2‐ versus IL‐15‐stimulated CD8 T cells in adoptive immunotherapy

We determined the efficacy of in vitro expanded P14 TCR transgenic CD8 T cells to mediate tumor cell elimination and to protect against viral infection in mice. Contrary to previous studies, an adoptive transfer model without lymphodepletion, vaccination or cytokine treatment was used. Antigen‐activated P14 T cells cultured in IL‐2‐containing medium for 7 days (P14IL‐2) exhibited potent effector cell functions in vitro but did not confer protection against melanoma growth or viral infection. In contrast, P14 T cells cultured in IL‐15 (P14IL‐15) were highly effective in vivo although they displayed only moderate effector functions in vitro. Therapeutic efficacy correlated with the survival of the transferred T cells in the recipients: P14IL‐2 cells disappeared rapidly whereas P14IL‐15 cells persisted for prolonged time. Decreasing the IL‐2 concentration in the culture media improved in vivo survival and efficacy but also lowered the cell yield of the cultures. Finally, we could extend the findings with monoclonal P14 T cells to polyclonal CD8 T cells. Thus, in vitro expansion of antigen‐specific CD8 T cells in IL‐15 allowed the generation of substantial numbers of T cells without inducing terminally differentiated effector cells that turned out to be unfavorable in the transfer model examined here.

[1]  E. Wherry,et al.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.

[2]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[3]  A. Diefenbach,et al.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15. , 2007, Immunity.

[4]  T. Waldmann,et al.  The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.

[5]  C. Rooney,et al.  Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.

[6]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[7]  T. Waldmann The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[8]  Linda V. Sinclair,et al.  Differential regulation of T-cell growth by IL-2 and IL-15. , 2006, Blood.

[9]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[10]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[12]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[13]  P. Burkett,et al.  Coordinate Expression and Trans Presentation of Interleukin (IL)-15Rα and IL-15 Supports Natural Killer Cell and Memory CD8+ T Cell Homeostasis , 2004, The Journal of experimental medicine.

[14]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[15]  O. Bathe,et al.  Initial Antigen Encounter Programs CD8+ T Cells Competent to Develop into Memory Cells That Are Activated in an Antigen-Free, IL-7- and IL-15-Rich Environment1 , 2004, The Journal of Immunology.

[16]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[17]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Lefrançois,et al.  Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. , 2004, Blood.

[19]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[20]  E. Pamer,et al.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. , 2002, The Journal of clinical investigation.

[21]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[22]  T. Waldmann,et al.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.

[23]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[24]  Wolfgang Weninger,et al.  Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.

[25]  J. Lieberman,et al.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. , 2001, The Journal of clinical investigation.

[26]  T. Strom,et al.  IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.

[27]  M. Neuenhahn,et al.  Differential requirement of perforin and IFN‐γ in CD8 T cell‐mediated immune responses against B16.F10 melanoma cells expressing a viral antigen , 2000, European journal of immunology.

[28]  P. Marrack,et al.  Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.

[29]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[30]  T. Dassopoulos,et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.

[31]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[32]  D. Cosman,et al.  IL‐15, a novel T cell growth factor that shares activities and receptor components with IL‐2 , 1995, Journal of leukocyte biology.

[33]  Hans Hengartner,et al.  T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides , 1993, European journal of immunology.

[34]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[35]  R M Zinkernagel,et al.  Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. , 1991, Journal of virological methods.

[36]  S. Rosenberg,et al.  Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.

[37]  K. Smith,et al.  Interleukin-2 induction of T-cell G1 progression and c-myb expression. , 1986, Science.

[38]  M. Oldstone,et al.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. VI. Migration and activity in vivo in acute and persistent infection. , 1986, Journal of immunology.